Keyphrases
Sarcopenia
100%
Physical Performance
95%
Leucine
71%
Randomized Controlled Trial
57%
Muscle Mass
54%
Older People
53%
Perindopril
47%
Genotype
41%
Short Physical Performance Battery
33%
Arm Fat
31%
Meta-analysis
31%
Treatment Effect
29%
Fat Mass
27%
Body Composition
27%
Renin-angiotensin System Inhibitors
23%
Systematic Meta-analysis
23%
BDKRB2
23%
Bradykinin B2 Receptor
23%
Type I Receptor
23%
Older Individuals
23%
Activin
23%
Receptor Polymorphisms
23%
Angiotensin Receptor Blockers
21%
Angiotensin-converting Enzyme Inhibitor (ACEi)
21%
Placebo
19%
Standardized Mean Difference
19%
Muscle Strength
15%
I(2)
14%
6-minute Walk Distance (6MWD)
14%
ACVR1B
11%
Polymorphism
11%
ACE Inhibitors
11%
Female Sex
10%
Adverse Events
9%
TT Genotype
7%
Lower Arm
7%
Genotype Frequency
7%
Leg muscles
7%
Between-group Difference
7%
Confidence Interval
7%
Gait Speed
6%
Regional Body Composition
5%
Leg Fat Mass
5%
Aging
5%
Fat Accumulation
5%
Signaling Pathway
5%
Myostatin
5%
Young Males
5%
Human muscle
5%
Sectional Analysis
5%
Minor Allele Frequency
5%
Muscle Physiology
5%
Polymorphic Variation
5%
Myostatin Signaling
5%
Minor Allele
5%
Patient Benefit
5%
Factorial Trial
5%
Clinically Significant
5%
Placebo-controlled
5%
Grip Strength
5%
Physical Function
5%
Low muscle Mass
5%
12-month Follow-up
5%
Medicine and Dentistry
Sarcopenia
100%
Physical Performance
95%
Randomized Controlled Trial
80%
Leucine
71%
Perindopril
47%
Arm
35%
ACE Inhibitor
35%
Meta-Analysis
34%
Treatment Effect
29%
Systematic Review
28%
Placebo
24%
Angiotensin
23%
Activin Receptor 1
23%
Bradykinin B2 Receptor
23%
Angiotensin Receptor Antagonist
21%
Allele
17%
Activin
17%
Muscle Strength
14%
Leg Muscle
11%
Receptor
11%
Myostatin
11%
Muscle Function
10%
Adverse Event
9%
Walking Speed
8%
Biological Marker
7%
Athletic Performance
5%
Athletes
5%
Leg
5%
Cross Sectional Study
5%
Gene Frequency
5%
Lipid Storage
5%
Signal Transduction
5%
Dual-Energy X-Ray Absorptiometry
5%